T hree decades after urologist Ramon Cabanas, M.D., made the first published reference to the "so-called sentinel lymph node," the role and utility of sentinel lymph node (SLN) evaluation in cancer continues to provide fuel for debate. In particular, oncologists are still arguing the clinical significance of microme tastases in sentinel nodes of breast cancer patients.
Removing the lymph nodes under the arm, called axillary lymph node dissection (ALND), has been the traditional approach to breast cancer staging. Un questionably accu rate for determining whether breast cancer has spread to the lymph nodes, ALND can result in substantial long-term problems, including loss of arm sensation and movement. Since the early 1990s, SLN biopsy has emerged as a less invasive approach to determine whether cancer has spread to the lymph nodes. However, questions have persisted about SLN biopsy's relative accuracy compared to ALND.
The Seemingly contradictory results emerged from a retrospective analysis of 702 Italian breast cancer patients who had nanometastases ( £ 0.2 mm) or micrometastases in SLNs. Nanometastases predicted worse survival than that of patients with negative nodes, but the presence of the larger micrometastases did not infl uence survival. In an update of the Italian study, reported at the San Antonio meeting, the disparate fi ndings relative to the clinical signifi cance of nanometastases versus micrometastases persisted. When the microscopic and submicroscopic disease categories were combined, disease-free survival did not differ from that of patients who had node-negative disease. The risk of distant metastasis was increased when the two categories were considered together.
"Nanometastases are a strong risk factor for all adverse events and for disease relapse," said Saverio Alberti, M.D., Ph.D., head of experimental oncology at the University of Chieti in Italy. "The lack of a size threshold indicates that lymph node deposits are bona fi de metastases at very early stages of disease. The constant risk of relapse over time supports an unvaried capacity to metastasize over the years."
Hungarian investigators performed a meta-analysis of 25 studies in an attempt to quantify the likelihood that cancer would be found in a non-SLN after the discovery of micrometastases or isolated tumor cells in SLNs. The analysis revealed non-SLN involvement in about 20% of cases. If SLN involvement was detected by IHC alone, the incidence of non-SLN involvement was about 9%.
Researchers at the European Institute of Oncology in Milan, Italy, examined the association between positive SLNs and additional axillary metastases in 3,600 breast cancer patients, 1,228 of whom had node-positive disease. The presence of micrometastases in 318 patients' SLNs predicted additional axillary in volvement in 68 cases (21.4%). Isolated tumor cells were identifi ed in 116 patients, 17 (14.7%) of whom had other axillary metastases.
Because of the mixed fi ndings, Rutgers said pathologists should be asked to look only for disease that has known clinical relevance. If ALND in patients with micrometastases fails to identify involvement beyond the SLN, the disease should be considered node negative, and adjuvant therapy should be based on the primary tumor's prognostic features.
"The prognostic signifi cance of micrometastases for survival is unclear and at most limited," Rutgers said. "The primary tumor characteristics, such as size and grade, are the most important prognostic factors." 
N E W S Guiding Staging
Even though the debate is still raging, physicians use the presence of microscopic metastases to infl uence treatment. Netherlands Cancer Institute investigators in Amsterdam examined micrometastases' ability to predict non-SLN involvement and infl uence clinical management. They reviewed data on 2,150 patients, 650 (30%) of whom had positive SLNs, including 254 (12%) patients who had micrometastases or isolated tumor cells. This fi nding resulted in a difference in staging in 15% of cases involving micrometastases, and treatment was altered in 7%. The presence of isolated tumor cells led to a change in stage in 4% of cases, and no patient's treatment was affected. This fi nding is important because a change in stage can affect how the cancer is treated.
Staging infl uences another important part of the SLN debate: the degree of side effects with the different surgeries. A randomized trial comparing SLN biopsy alone and SLN biopsy followed by routine ALND corroborated previous evidence that SLN biopsy alone is associated with fewer problems. However, the results did not answer the question of whether the risk of cancer recurrence differs between the two techniques.
The study involved 1,088 patients in Australia and New Zealand who had single tumors less than 3 cm in size and clinically negative axillary lymph nodes, said P. Grantley Gill, M.D., head of breast, endocrine, and surgical oncology at the Royal Adelaide Hospital in Australia. At the fi rst follow-up, more patients in the routine axillary clearance group had infections (14% versus 9% with biopsy) and seromas (36% versus 17%), and arm swelling was more pronounced in the routine axillary clearance patients than that in the biopsy group. The proportion of patients with a more than 15% increase in arm volume was 7.1% with routine axillary clearance and 4.2% with SLN biopsy.
"Sentinel node biopsy leads to substantially less morbidity than axillary clearance based on both objective clinicians' measurements and subjective patient-rated outcome measures," Gill said. "Differences in arm mobility diminished over time. Differences in arm swelling increased over time." Defi nitive answers about cancer recurrence associated with biopsy versus routine axillary clearance require a comprehensive meta-analysis of all randomized trials, he concluded.
